Dr Solange Peters reviews data from POSEIDON on combination durvalumab, tremelimumab, and chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) that were recently presented at the 2022 World Conference on Lung Cancer.
Solange Peters, MD, PhD
Advertisement
Articles by Solange Peters, MD, PhD
Solange Peters, MD, PhD, discusses ongoing research with fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) in patients with HER2-mutated non–small cell lung cancer.
Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.
Solange Peters, MD, PhD, head of the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne in Switzerland, discusses the FLAURA trial for patients with EGFR-mutated non
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5